NDA 210251 · Gilead Sciences INC
Biktarvy
Bictegravir Sodium, Emtricitabine, Tenofovir Alafenamide Fumarate · Oral · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Feb 7, 2018
Approved uses
9
Original approval plus efficacy supplements
Registered trials
120
36 Phase 3, 12 recruiting
FAERS reports
18,385
13,377 serious, 732 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients with HIV-1 and HBV who discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with...
What it is approved for
From the label in effect Sep 9, 2026.
BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: with no antiretroviral treatment history, or with an antiretroviral treatment history and not virologically suppressed, with no known or suspected substitutions associated with resistance to the integrase strand inhibitor class, emtricitabine, or tenofovir, or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir [see Dosage and Administration (2.4) , and Use in Specific Populations (8.1) ]. BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg: with no antiretroviral treatment history or with an antiretroviral treatment history and not virologically suppressed, with no known or suspected substitutions associated with resistance to the integrase strand inhibitor class, emtricitabine, or tenofovir, or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. ( 1 )
Mechanism: BIKTARVY is a fixed dose combination of antiretroviral drugs bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 30, 2025 Supplement 23 · Efficacy OrphanLabelLetter
- Apr 24, 2024 Supplement 19 · Efficacy · priority review OrphanLetterLabel
- Feb 23, 2024 Supplement 18 · Efficacy OrphanLabelLetter
- Oct 14, 2022 Supplement 15 · Efficacy LetterLabel
- Oct 7, 2021 Supplement 14 · Efficacy · priority review OrphanLetterLabel
- Feb 24, 2021 Supplement 8 · Efficacy LetterLabel
- Feb 5, 2021 Supplement 7 · Efficacy LabelLetter
- Jun 18, 2019 Supplement 5 · Efficacy · priority review OrphanLetterLabel
- Feb 7, 2018 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelOrphanLabelLetterReview
2 products under this application
- BIKTARVY · BICTEGRAVIR SODIUM EQ 50MG BASE; EMTRICITABINE 200MG; TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE · TABLET, ORAL · Prescription
- BIKTARVY · BICTEGRAVIR SODIUM EQ 30MG BASE; EMTRICITABINE 120MG; TENOFOVIR ALAFENAMIDE FUMARATE EQ 15MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bictegravir" as an intervention, any sponsor and status, largest first.
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07708727 · 700 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 2030
Drug: GS-3242 Tablet; GS-3242 Injection and 3 more · For: HIV-1-infection
Sites: Torrance, California; New Haven, Connecticut; Ft. Pierce, Florida · 21 sites in all
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502341 · 689 participants · Start Aug 16, 2022 · Primary completion Sep 29, 2025
Drug: Bictegravir; Lenacapavir and 2 more · For: HIV-1-infection
Sites: Berkeley, California; Beverly Hills, California; Los Angeles, California · 94 sites in all
ViiV HealthcareGSK (GSK)
NCT04542070 · 687 participants · Start Nov 9, 2020 · Primary completion Jul 13, 2022
Drug: Cabotegravir Tablets; Cabotegravir Injectable Suspension (CAB LA) and 3 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Los Angeles, California · 117 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02607956 · 657 participants · Start Nov 11, 2015 · Primary completion May 12, 2017
Drug: DTG; F/TAF and 4 more · For: HIV-1 Infection
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 125 sites in all
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04223791 · 643 participants · Start Feb 18, 2020 · Primary completion Aug 26, 2021
Drug: DOR/ISL; BIC/FTC/TAF and 2 more · For: HIV Infection
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 89 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02607930 · 631 participants · Start Nov 13, 2015 · Primary completion May 9, 2017
Drug: ABC/DTG/3TC; B/F/TAF and 2 more · For: HIV-1 Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 121 sites in all
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06630286 · 609 participants · Start Oct 9, 2024 · Primary completion Apr 17, 2026
Drug: ISL/LEN; B/F/TAF and 2 more · For: HIV-1-infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 106 sites in all
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06630299 · 600 participants (planned) · Start Oct 8, 2024 · Primary completion Apr 23, 2026
Drug: ISL/LEN; Antiretroviral Combinations · For: HIV-1-Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bone density decreased6,649
- chronic kidney disease3,668
- bone loss3,491
- tooth loss3,445
- osteonecrosis3,405
- multiple fractures3,153
- renal failure3,059
- osteoporosis2,794
- pain2,549
- renal injury2,489
- emotional distress2,436
- anxiety2,283
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2015 | 1 |
| 2016 | 7 |
| 2017 | 1 |
| 2018 | 363 |
| 2019 | 1,482 |
| 2020 | 5,609 |
| 2021 | 2,570 |
| 2022 | 2,257 |
| 2023 | 1,630 |
| 2024 | 1,854 |
| 2025 | 1,709 |
| 2026 | 901 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Biktarvy (Bictegrav/Emtricit/Tenofov Ala)
2024 spending
$3.46B
Beneficiaries
92,246
840,772 claims
Per beneficiary
$37,466
$131.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,775,846,507 |
| 2021 | $2,198,270,149 |
| 2022 | $2,703,581,195 |
| 2023 | $3,152,256,269 |
| 2024 | $3,456,061,331 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Multicenter Study
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, et al. · Lancet HIV 2020 · Clinical Trial, Phase III, Comparative Study
- Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Rockstroh JK, Ramgopal MN, Curran Fàbregas A, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy.
Andreatta K, Sax PE, Wohl D, et al. · J Antimicrob Chemother 2025 · Clinical Trial, Phase III, Comparative Study
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial.
Avihingsanon A, Lu H, Leong CL, et al. · Lancet HIV 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.